However, generation of new founder transgenic mice every time as well as BCR-ABL toxicity and silencing for establishing CML transgenic models remains a cumbersome and challenging effort. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.